Worldwide Cancer Molecular Diagnostics Industry to 2025 – Personalized Medicine and Pharmacogenomics are Driving Growth

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read more

Worldwide Cancer Molecular Diagnostics Industry to 2025

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read more

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

Companies to collaborate in first-of-its-kind uses of Thin Film Freezing technology applied to monoclonal antibodies

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling, today jointly announce that both companies have entered into a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.

Under the terms of the Agreement, both companies will collaborate in a Joint Development Project to develop one or more commercial therapeutics based on, derived from, and/or incorporating Augmenta’s human monoclonal antibodies to potentially treat patients with COVID-19. These products will be developed utilizing TFF Pharmaceuticals’ Thin-Film Freezing technology to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients. The Agreement also includes the development of formulations suitable for parenteral administration, where the Thin Film Freezing dry powder formulations can be reconstituted, potentially mitigating the impacts of cold-chain storage and handling. TFF Pharmaceuticals will also have the option to develop two additional Augmenta mAbs for indications other than COVID-19.

Augmenta Bioworks and TFF Pharmaceuticals will allocate patent license rights to their respective technologies to allow each company to jointly commercialize the products developed under the Joint Development Project. The companies have agreed to a 50-50 split of all costs and expenses to further the Joint Development Project and both companies have agreed to the same 50-50 split of all revenues, cash payments and/or future cash payments related to the sale and/or license of the products resulting from the Joint Development Project to a third party.

“This important agreement represents the culmination of many months of work by our scientific team, as we work towards the development of a never-before-achieved formulation of monoclonal antibodies into a dry powder therapeutic,” said Glenn Mattes, CEO, of TFF Pharmaceuticals, Inc. “It is a testament to the remarkable flexibility and capability of our Thin Film Freezing platform and we are eager to develop these potentially breakthrough mAb therapies internally, along with our other programs in Invasive Pulmonary Aspergillosis, solid organ transplant anti-rejection, and botanicals.”

“Confirmed discovery of novel anti-SARS-Cov-2 antibodies in 8 days was an achievement made possible by years of technology development, and a clear indication of the power and potential of our platform,” said Christopher Emig, Ph.D., CEO and Co-Founder of Augmenta Bioworks, Inc. “We are excited to enter this partnership to bring our COVID-19 treatment into clinical development, and are looking forward to the world’s first effective, affordable and scalable antibody therapeutic to mitigate the devastating effects of this disease.”

“We believe the interest in monoclonal-antibody therapeutics for the treatment of COVID-19 is extremely high, with the promise that they will harness the immune system’s natural response to viral invaders,” said Robert O. Williams III, Ph.D., Division Head of the University of Texas at Austin’s Division of Molecular Pharmaceutics and Drug Delivery and inventor of TFF Pharmaceuticals’ Thin Film Freezing technology.

“The challenge

Read more

Governments Worldwide Consider Ditching Daylight Saving Time

It’s nearly that time of the year again: the end of daylight saving, when Americans push their clocks back and rejoice at the gained hour of sleep—or mourn the lost hour of sunlight in the afternoon.

This system’s twice-a-year transitions have become increasingly unpopular. Scientists have been calling attention to the damaging effects of the time changes—which include a general reduction in mental and physical well-being, as well as a potential increased risk of serious complications, such as strokes and heart attacks, soon after the shifts. There is also evidence of increases in traffic fatalities and harmful medical errors shortly following when clocks are moved forward in the spring.

In many countries, this might be the one of the last instances in which people make the adjustment. Governments around the world have been in discussions about scrapping the seasonal clock changes and sticking to one time—either permanent standard time or permanent daylight saving. In the U.S., many states are considering, or have already passed, legislation to adopt one of the two. Hawaii and most of Arizona decided to adopt just standard time  more than 50 years ago. Last year the European Parliament voted to abolish the time shifts, but the member states of the European Union have yet to agree on how to implement the decision.

Beth Malow, a professor of neurology and pediatrics at Vanderbilt University, spoke with Scientific American about the health effects of this timekeeping practice and what should replace it.

[An edited transcript of the interview follows.]

The end of daylight saving time is fast approaching. Generally speaking, how disruptive are the transitions to and from daylight saving to physical and mental well-being?

There’s a lot of variability in what people experience. Some people have shared with me that, for example, they might have a child with autism, and for two or three months after the transition, they feel like things are just not right with their child’s sleep. People also tell me they just feel out of sync for a while. Other people may deal with the change more easily. It’s similar to when we travel [from the U.S.] to Europe. Some people are affected by jet lag more than others.

The one thing I will say is that people think, “Well, it’s only an hour, so it’s not a big deal. It’s kind of like traveling from Nashville, [Tenn.], to New York [City]—going from Central to Eastern time.” But [daylight saving] really isn’t that. It’s a misalignment of your biological rhythms, or circadian rhythms, for eight months out of the year.

You wrote a commentary in JAMA Neurology last year that discusses some medical complications—such as cardiovascular problems and stroke—associated with the transitions. Can you talk a bit about how daylight saving changes can increase the risk for these kinds of events?

We don’t know the actual mechanism because these are epidemiological studies, where there are large numbers of people, and [researchers] observe the stroke rate or heart attack rate increase

Read more

Tuberculosis is a major worldwide threat and the pandemic could make it worse, WHO says

In a new report, WHO provides a global update on the state of TB and the fight against the disease, which is both preventable and curable.

The report paints a dire picture of a disease that remains a public health crisis. Just eight countries — India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa — account for two-thirds of the world’s TB cases. And because many carriers of the disease are not yet ill, it can go untreated until it’s too late.

Tuberculosis incidences are falling, the agency says — between 2015 and 2019, cases were reduced by about 9 percent. But that still falls short of WHO’s targets.

The coronavirus pandemic is expected to make things worse.

Large drops occurred in TB diagnoses between January and June. Due to the economic effects of the pandemic, WHO models predict that cases could annually increase by more than 1 million in the next five years if resources continue to be diverted to covid-19, the disease caused by the coronavirus.

The stark report has positive news however. Funding for TB prevention, diagnosis and treatment has doubled since 2006, and seven high-burden countries reached their death reduction milestone. And people living with HIV are more likely than ever to be given preventive treatment for tuberculosis, which is the leading killer of people with HIV worldwide.

The report is available online or as an interactive app. To download, visit bit.ly/TBreportapp.

Source Article

Read more

Coronavirus cases top 40M worldwide

The number of coronavirus cases worldwide has surpassed 40 million, according to data from Johns Hopkins University.

The world hit the new high-water mark amid a “second wave” that has built since August in Europe. Various European government officials have reintroduced restriction and closures of businesses like bars and restaurants, CNBC noted.

Some European nations have also implemented curfews in response to the second wave.  Slovenia, for example, will impose one for the first time from 9 p.m. to 6 a.m. beginning Tuesday, according to The Associated Press. France and Belgium have imposed similar curfews. In May, Slovenia became Europe’s first to declare its epidemic over after the rate of new cases slowed to only a few daily.

Europe has now surpassed the U.S. in number of new infections per 1 million people, according to CNBC. As of Monday, the U.S. reported a seven-day average of 162 cases per 1 million people, compared to 187 per million in Europe, according to CNBC.

World Health Organization data, meanwhile, puts the total worldwide figure slightly lower, at 39.8 million. This includes 18.7 million cases in the Americas, 8.5 million in Southeast Asia, 7.9 million in Europe and just 1.26 million in Africa.

The U.S., India and Brazil remain the three hardest-hit countries, according to a Reuters analysis. Daily increases are up around 347,000 cases over the past week in each nation, an increase of more than 50,000 per day from the first week of October.

In Europe, according to the Reuters analysis, new case growth is over 150,000 a day. This includes record daily jumps in the Netherlands, Germany, Austria, Poland, Ukraine, Cyprus, the Czech Republic and Italy, which was the original European epicenter of the virus. Seventeen percent of global cases and almost 22 percent of deaths worldwide are in Europe, according to the news service.

Source Article

Read more

Hemoglobin Testing Market | Growing Incidence of Diabetes Worldwide to Boost Market Growth

The global hemoglobin testing market size is poised to grow by USD 612.82 million during 2020-2024, progressing at a CAGR of almost 8% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201016005222/en/

Technavio has announced its latest market research report titled Global Hemoglobin Testing Market 2020-2024 (Graphic: Business Wire)

Globally, the prevalence of diabetes has significantly increased over the decades. This can be attributed to sedentary lifestyles, obesity, and lack of physical activity. The prevalence of diabetes is growing significantly in countries across the Middle East such as Iran, where around 24% of the people aged over 40 have diabetes. In the UAE, more than 16% of the total population aged 20-79 years had diabetes in 2019. The rising prevalence of diabetes has increased the demand for effective and advanced hemoglobin testing devices to monitor glucose levels, thereby driving the growth of the market.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major hemoglobin testing market growth came from the healthcare centers segment in 2019. This is due to the increasing number of hospitals in developing countries and the growing trend of medical tourism.

  • North America was the largest market for hemoglobin testing in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. This is attributed to the increasing prevalence of obesity and diabetes in the region.

  • The global hemoglobin testing market is fragmented. Abbott Laboratories, ACON Laboratories Inc., Bayer AG, Bio-Rad Laboratories Inc., Danaher Corp., Diazyme Laboratories Inc., EKF Diagnostics Holdings Plc, F. Hoffmann-La Roche Ltd., Siemens AG, and Thermo Fisher Scientific Inc. are some of the major market participants. To help clients improve their market position, this hemoglobin testing market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the global hemoglobin testing market 2020-2024 is expected to have neutral growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.

Read the full report here: https://www.technavio.com/report/hemoglobin-testing-market-industry-analysis

Growing preference for home care settings will be a Key Market Trend

Over the years, the demand for homecare blood testing devices has increased across the globe. This is because home care testing devices provide faster results and help patients better manage their disease. They also reduce the overall investigation time and the number of visits to hospitals outpatient department and diagnostic laboratories. This has encouraged vendors in the market to offer a wide range of diagnostics devices that are ideal for home use. For instance, PTS

Read more